Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fatostatin A 是一种SREBP 活化的特异性抑制剂,能够抑制 SREBP-1 和 SREBP-2 的活化。它与 SCAP (SREBP 裂解激活蛋白) 结合,抑制 SREBPs 的 ER-Golgi 易位。它具有抗肿瘤活性,能抑制ob/ob 小鼠的高血糖。它抑制细胞中成脂基因的转录。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 237 | 现货 | ||
2 mg | ¥ 336 | 现货 | ||
5 mg | ¥ 521 | 现货 | ||
10 mg | ¥ 798 | 现货 | ||
25 mg | ¥ 1,800 | 现货 | ||
50 mg | ¥ 2,930 | 现货 | ||
100 mg | ¥ 4,260 | 现货 | ||
200 mg | ¥ 5,920 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 589 | 现货 |
产品描述 | Fatostatin is a specific inhibitor of SREBP activation, it impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. |
体外活性 | Fatostatin directly binds SCAP and blocks its ER-to-Golgi transport with IC50 of 2.5 and 10 μM in mammalian cells[1]. Fatostatin (0.1-1 μM; 3 days) inhibits the androgen-independent prostate cancer cell proliferation (IC50=0.1 μM) in an independent of the known IGF1-signaling pathway. Fatostatin inhibits insulin-induced adipogenesis of 3T3-L1 cells[2]. |
体内活性 | Fatostatin (30 mg/kg; i.p. injection; daily for 28 days) reduces adiposity, ameliorated fatty liver by reducing triglyceride (TG) storage, and lowered hyperglycemia in ob/ob mice[1]. |
分子量 | 294.41 |
分子式 | C18H18N2S |
CAS No. | 125256-00-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 70 mg/mL (237.76 mM)
H2O: Insoluble
Ethanol: 70 mg/mL (237.76 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 3.3966 mL | 16.9831 mL | 33.9662 mL | 84.9156 mL |
5 mM | 0.6793 mL | 3.3966 mL | 6.7932 mL | 16.9831 mL | |
10 mM | 0.3397 mL | 1.6983 mL | 3.3966 mL | 8.4916 mL | |
20 mM | 0.1698 mL | 0.8492 mL | 1.6983 mL | 4.2458 mL | |
50 mM | 0.0679 mL | 0.3397 mL | 0.6793 mL | 1.6983 mL | |
100 mM | 0.034 mL | 0.1698 mL | 0.3397 mL | 0.8492 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Fatostatin 125256-00-0 Metabolism Lipid Fatty Acid Synthase mice 125B11 prostate cancer Fatty Acid Synthase (FASN) gene human insulin-induced ob/ob inhibit expression Golgi Inhibitor adipogenesis SREBP-mediated inhibitor